Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 1Breast 1

Conditions

Prostatic Neoplasms 23Breast Neoplasms 3Triple Negative Breast Neoplasms 2Prostate Adenocarcinoma 2Neoplasm Metastasis 2Stage I Prostate Adenocarcinoma AJCC v7 1Salivary Gland Neoplasms 1Primary Dysautonomias 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Non-Muscle Invasive Bladder Urothelial Carcinoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Kidney Diseases 1Hypertension 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Bulbo-Spinal Atrophy, X-Linked 1

Interventions

pembrolizumab 105Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 43Paclitaxel 36Gemcitabine 30Radiosurgery 29Carboplatin 29Ipilimumab 24Irinotecan 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Capecitabine 20Leucovorin 19Pemetrexed 18Fulvestrant 18Fluorouracil 18Cetuximab 18130-nm albumin-bound paclitaxel 18Docetaxel 17Bevacizumab 17Taxes 16Oxaliplatin 16Drug Therapy 16olaparib 15abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × bicalutamide × 1 year × Clear all
NCT05095207 2026-04-13

Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer

Icahn School of Medicine at Mount Sinai

Phase 1/2 Recruiting
42 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04787744 2026-04-08

VA STARPORT

VA Office of Research and Development

Phase 2/3 Recruiting
464 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡